M. Basche

703 total citations
21 papers, 528 citations indexed

About

M. Basche is a scholar working on Oncology, Molecular Biology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, M. Basche has authored 21 papers receiving a total of 528 indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Oncology, 11 papers in Molecular Biology and 4 papers in Pulmonary and Respiratory Medicine. Recurrent topics in M. Basche's work include Colorectal Cancer Treatments and Studies (7 papers), Cancer Treatment and Pharmacology (7 papers) and Cancer therapeutics and mechanisms (3 papers). M. Basche is often cited by papers focused on Colorectal Cancer Treatments and Studies (7 papers), Cancer Treatment and Pharmacology (7 papers) and Cancer therapeutics and mechanisms (3 papers). M. Basche collaborates with scholars based in United States, Australia and Germany. M. Basche's co-authors include Scott N. Holden, Lia Gore, Sabine Eckhardt, Mark Morrow, Daniel L. Gustafson, Cindy L. O’Bryant, Anna E. Barón, S. Gail Eckhardt, William J. Buikema and Robert Haselkorn and has published in prestigious journals such as Journal of Clinical Oncology, Clinical Cancer Research and Endocrinology.

In The Last Decade

M. Basche

20 papers receiving 511 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
M. Basche United States	12	313	139	98	58	57	21	528
Eun‐Kyoung Breuer United States	13	309 1.0×	181 1.3×	66 0.7×	12 0.2×	65 1.1×	17	475
Alessia Calzolari Italy	12	272 0.9×	92 0.7×	36 0.4×	14 0.2×	37 0.6×	16	636
Hsi Chin Wu Taiwan	11	216 0.7×	130 0.9×	40 0.4×	19 0.3×	203 3.6×	22	502
Carmen G. Lechuga Spain	13	474 1.5×	161 1.2×	109 1.1×	10 0.2×	31 0.5×	26	698
Matthew W. Strobeck United States	14	911 2.9×	342 2.5×	88 0.9×	9 0.2×	79 1.4×	17	1.1k
Annemarie Larkin Ireland	18	477 1.5×	318 2.3×	45 0.5×	15 0.3×	60 1.1×	32	770
Uri Sagman Canada	11	381 1.2×	461 3.3×	44 0.4×	32 0.6×	231 4.1×	19	905
Kévin Ly Canada	11	218 0.7×	74 0.5×	58 0.6×	16 0.3×	22 0.4×	20	530
JI Epstein United States	4	334 1.1×	202 1.5×	26 0.3×	16 0.3×	200 3.5×	6	598
Hannah J. Lomax-Browne United Kingdom	11	312 1.0×	106 0.8×	55 0.6×	45 0.8×	66 1.2×	15	752

Countries citing papers authored by M. Basche

Since Specialization

Citations

This map shows the geographic impact of M. Basche's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by M. Basche with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites M. Basche more than expected).

Fields of papers citing papers by M. Basche

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by M. Basche. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by M. Basche. The network helps show where M. Basche may publish in the future.

Co-authorship network of co-authors of M. Basche

This figure shows the co-authorship network connecting the top 25 collaborators of M. Basche. A scholar is included among the top collaborators of M. Basche based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with M. Basche. M. Basche is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Jameson, Gayle, John Hamm, Glen J. Weiss, et al.. (2012). A Multicenter, Phase I, Dose-Escalation Study to Assess the Safety, Tolerability, and Pharmacokinetics of Etirinotecan Pegol in Patients with Refractory Solid Tumors. Clinical Cancer Research. 19(1). 268–278. 43 indexed citations

Gore, Lia, M. Basche, Stacy Moulder-Thompson, et al.. (2011). Phase I combination study of trabectedin and capecitabine in patients with advanced malignancies. Investigational New Drugs. 30(5). 1942–1949. 9 indexed citations

Chow, Laura Q.M., Daniel L. Gustafson, Cindy L. O’Bryant, et al.. (2008). A phase I pharmacological and biological study of PI-88 and docetaxel in patients with advanced malignancies. Cancer Chemotherapy and Pharmacology. 63(1). 65–74. 19 indexed citations

Lam, Elaine T., Cindy L. O’Bryant, M. Basche, et al.. (2008). A phase I study of gefitinib, capecitabine, and celecoxib in patients with advanced solid tumors. Molecular Cancer Therapeutics. 7(12). 3685–3694. 6 indexed citations

Silberman, Simone, Jong Ha Hwang, John L. Marshall, et al.. (2008). A phase I study of TPI 287, a novel taxane, administered weekly in patients with advanced cancer. Journal of Clinical Oncology. 26(15_suppl). 2536–2536. 3 indexed citations

Modiano, Manuel, Patricia M. Plezia, M. Basche, et al.. (2008). A phase I study of TPI 287, a novel taxane, administered every 21 days in patients (pts) with advanced cancer. Journal of Clinical Oncology. 26(15_suppl). 13510–13510. 4 indexed citations

Basche, M., Anna E. Barón, Sabine Eckhardt, et al.. (2008). Barriers to Enrollment of Elderly Adults in Early-Phase Cancer Clinical Trials. Journal of Oncology Practice. 4(4). 162–168. 49 indexed citations

Chow, Laura Q.M., Sabine Eckhardt, Cindy L. O’Bryant, et al.. (2007). A phase I safety, pharmacological, and biological study of the farnesyl protein transferase inhibitor, lonafarnib (SCH 663366), in combination with cisplatin and gemcitabine in patients with advanced solid tumors. Cancer Chemotherapy and Pharmacology. 62(4). 631–646. 22 indexed citations

Hariharan, Seetharaman, Daniel L. Gustafson, Scott N. Holden, et al.. (2007). Assessment of the biological and pharmacological effects of the ανβ3 and ανβ5 integrin receptor antagonist, cilengitide (EMD 121974), in patients with advanced solid tumors. Annals of Oncology. 18(8). 1400–1407. 97 indexed citations

10.

Modiano, Manuel, Patricia M. Plezia, Jacob Baram, et al.. (2007). A phase I study of TPI 287, a third generation taxane, administered every 21 days in patients with advanced cancer. Journal of Clinical Oncology. 25(18_suppl). 2569–2569. 2 indexed citations

11.

Basche, M., Daniel L. Gustafson, Scott N. Holden, et al.. (2006). A Phase I Biological and Pharmacologic Study of the Heparanase Inhibitor PI-88 in Patients with Advanced Solid Tumors. Clinical Cancer Research. 12(18). 5471–5480. 77 indexed citations

12.

Green, Lisa J., Philip Marder, Chad Ray, et al.. (2006). Development and Validation of a Drug Activity Biomarker that Shows Target Inhibition in Cancer Patients Receiving Enzastaurin, a Novel Protein Kinase C-β Inhibitor. Clinical Cancer Research. 12(11). 3408–3415. 38 indexed citations

13.

Leong, Stephen, D. Ross Camidge, Gail Eckhardt, et al.. (2006). A phase I dose-escalation and pharmacokinetic study of enzastaurin combined with capecitabine in patients with advanced cancer. Journal of Clinical Oncology. 24(18_suppl). 2048–2048. 9 indexed citations

14.

Kobayashi, Hiroyuki, S. Gail Eckhardt, Jennifer A. Lockridge, et al.. (2005). Safety and pharmacokinetic study of RPI.4610 (ANGIOZYME), an anti-VEGFR-1 ribozyme, in combination with carboplatin and paclitaxel in patients with advanced solid tumors. Cancer Chemotherapy and Pharmacology. 56(4). 329–336. 28 indexed citations

15.

Basche, M., Alan Baron, S. Gail Eckhardt, et al.. (2005). A semi-quantitative survey of older adults to assess barriers to participation in early phase clinical trials (EPCTs). Journal of Clinical Oncology. 23(16_suppl). 8086–8086.

16.

Gore, Lia, Scott N. Holden, M. Basche, et al.. (2004). Updated results from a phase I trial of the histone deacetylase (HDAC) inhibitor MS-275 in patients with refractory solid tumors. Journal of Clinical Oncology. 22(14_suppl). 3026–3026. 17 indexed citations

17.

Witta, Samir E., Daniel L. Gustafson, A. Scott Pierson, et al.. (2004). A Phase I and Pharmacokinetic Study of Exisulind and Docetaxel in Patients with Advanced Solid Tumors. Clinical Cancer Research. 10(21). 7229–7237. 22 indexed citations

18.

Basche, M., et al.. (1991). Importance of Morphological Findings in the Progress and Treatment of Chest Wall Deformities with Special Reference to the Value of Computed Tomography, Echocardiography and Stereophotogrammetry*. European Journal of Pediatric Surgery. 1(5). 291–297. 8 indexed citations

19.

Borthakur, Dulal, et al.. (1990). Expression, nucleotide sequence and mutational analysis of two open reading frames in the nif gene region of Anabaena sp. strain PCC 7120. Molecular and General Genetics MGG. 221(2). 227–234. 48 indexed citations

20.

Basche, M., Wesley G. Beamer, & Arthur B. Schneider. (1989). Abnormal Properties of Thyroglobulin in Mice with Inherited Congenital Goiter (cog/cog)*. Endocrinology. 124(4). 1822–1829. 23 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact